2026–2027 COVID-19 Vaccine Recommendations

Current U.S. guidance as of September 22, 2026

Organization	2026–27 Recommendation / FDA Indication	Source
FDA	≥65 years: approved regardless of risk factors. Ages 6 months–64 years: approval is limited to people with ≥1 underlying condition that puts them at high risk for severe COVID-19 outcomes. For pediatrics, Spikevax is approved beginning at 6 months; Comirnaty beginning at 5 years; MNEXSPIKE and Nuvaxovid beginning at 12 years.	Comirnaty PI Spikevax PI MNEXSPIKE PI Nuvaxovid PI
AAFP	Recommends an updated vaccine for all adults ≥19 years. Adults ≥65 years should receive a second dose 6 months later. Recommends vaccination for all children 6–23 months; ages 2–18 years use a risk-based approach, with vaccination available when protection is desired.	AAFP 2026–27 guidance
AAP	Recommends vaccination for all children 6–23 months. For ages 2–18 years, recommends vaccination for those at increased risk; vaccination should also be offered when a parent or guardian desires protection.	AAP 2026–27 recommendations
ACOG	Recommends COVID-19 vaccination for individuals who are pregnant, postpartum, lactating, or contemplating pregnancy.	ACOG guidance
CDC / ACIP	No 2026–27 COVID-19 vaccine recommendation has been issued as of September 22, 2026. CDC's currently published COVID-19 clinical guidance remains for the 2025–26 season.	CDC current guidance

Pennsylvania pharmacy practice note: The PA State Board of Pharmacy has approved ACOG, AAP, and AAFP as competent authorities for immunization guidance under 49 Pa. Code § 27.403(e), and has approved FDA as a competent authority specifically for COVID-19 immunizations. These are additional options to CDC/ACIP guidance for immunization practice in Pennsylvania. PA State Board of Pharmacy notice